Advertisement

Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002−2006 and 2007−2011

Published:November 09, 2014DOI:https://doi.org/10.1016/j.amepre.2014.08.036

      Background

      Skin cancer, the most common cancer in the U.S., is a major public health problem. The incidence of nonmelanoma and melanoma skin cancer is increasing; however, little is known about the economic burden of treatment.

      Purpose

      To examine trends in the treated prevalence and treatment costs of nonmelanoma and melanoma skin cancers.

      Methods

      This study used data on adults from the 2002−2011 Medical Expenditure Panel Survey full-year consolidated files and information from corresponding medical conditions and medical event files to estimate the treated prevalence and treatment cost of nonmelanoma skin cancer, melanoma skin cancer, and all other cancer sites. Analyses were conducted in January 2014.

      Results

      The average annual number of adults treated for skin cancer increased from 3.4 million in 2002−2006 to 4.9 million in 2007−2011 (p<0.001). During this period, the average annual total cost for skin cancer increased from $3.6 billion to $8.1 billion (p=0.001), representing an increase of 126.2%, while the average annual total cost for all other cancers increased by 25.1%. During 2007−2011, nearly 5 million adults were treated for skin cancer annually, with average treatment costs of $8.1 billion each year.

      Conclusions

      These findings demonstrate that the health and economic burden of skin cancer treatment is substantial and increasing. Such findings highlight the importance of skin cancer prevention efforts, which may result in future savings to the healthcare system.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rogers H.W.
        • Weinstock M.A.
        • Harris A.R.
        • et al.
        Incidence estimate of nonmelanoma skin cancer in the United States, 2006.
        Arch Dermatol. 2010; 146: 283-287
        • U.S. Cancer Statistics Working Group
        United States Cancer Statistics: 1999−2010 Incidence and Mortality Web-Based Report.
        Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, Atlanta GA2013
        • Lomas A.
        • Leonardi‐Bee J.
        • Bath‐Hextall F.
        A systematic review of worldwide incidence of nonmelanoma skin cancer.
        Br J Dermatol. 2012; 166: 1069-1080
        • Edwards B.K.
        • Noone A.M.
        • Mariotto A.B.
        • et al.
        Annual report to the nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.
        Cancer. 2014; 120: 2190-2314
      1. Clinical Classifications Software (CCS) for ICD-9-CM. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville MD. www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.

      2. Agency for Healthcare Research and Quality. Using the appropriate price indices for analyses of health care expenditures or income across multiple years. meps.ahrq.gov/about_meps/Price_Index.shtml.

        • Kyle J.W.
        • Hammitt J.K.
        • Lim H.W.
        • et al.
        Economic evaluation of the US Environmental Protection Agency׳s SunWise program: sun protection education for young children.
        Pediatrics. 2008; 121: e1074-e1084
        • Shih S.T.
        • Carter R.
        • Sinclair C.
        • Mihalopoulos C.
        • Vos T.
        Economic evaluation of skin cancer prevention in Australia.
        Prev Med. 2009; 49: 449-453
        • Hirst N.
        • Gordon L.
        • Gies P.
        • Green A.C.
        Estimation of avoidable skin cancers and cost-savings to government associated with regulation of the solarium industry in Australia.
        Health Policy. 2009; 89: 303-311
        • Boniol M.
        • Autier P.
        • Boyle P.
        • Gandini S.
        Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis.
        BMJ. 2012; 345: e4757
        • Wehner M.R.
        • Shive M.L.
        • Chren M.M.
        • Han J.
        • Qureshi A.A.
        • Linos E.
        Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis.
        BMJ. 2012; 345: e5909
        • Wolff T.
        • Tai E.
        • Miller T.
        Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2009; 150: 194-198
        • Freedberg K.A.
        • Geller A.C.
        • Miller D.R.
        • Lew R.A.
        • Koh H.K.
        Screening for malignant melanoma: a cost-effectiveness analysis.
        J Am Acad Dermatol. 1999; 41: 738-745